HLUBF (H. Lundbeck AS) Cyclically Adjusted Revenue per Share: $9.06 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HLUBF H. Lundbeck AS HLUBF
78 GF Score
Price $5.50
GF Value $5.65
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is H. Lundbeck AS Cyclically Adjusted Revenue per Share?

H. Lundbeck AS HLUBF 78 Cyclically Adjusted Revenue per Share is $9.06 as of Mar. 2026. GuruFocus rates HLUBF with a GF Score™ of 78/100 and a GF Value™ of $5.65 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

H. Lundbeck AS's adjusted revenue per share for the three months ended in Mar. 2026 was $1.110. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $9.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, H. Lundbeck AS's average Cyclically Adjusted Revenue Growth Rate was -8.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -7.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -5.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of H. Lundbeck AS was 1.70% per year. The lowest was -7.30% per year. And the median was -2.45% per year.

As of today (2026-07-21), H. Lundbeck AS's current stock price is $5.50. H. Lundbeck AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $9.06. H. Lundbeck AS's Cyclically Adjusted PS Ratio of today is 0.61.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of H. Lundbeck AS was 0.62. The lowest was 0.27. And the median was 0.44.


H. Lundbeck AS  (OTCPK:HLUBF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

H. Lundbeck AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.50/9.06
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of H. Lundbeck AS was 0.62. The lowest was 0.27. And the median was 0.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


H. Lundbeck AS Cyclically Adjusted Revenue per Share Related Terms


H. Lundbeck AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Cyclically Adjusted Revenue per Share Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 12.12 10.55 9.18 9.47

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.34 8.13 10.24 9.47 9.06

HLUBF vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Cyclically Adjusted PS Ratio falls into.


HLUBF
78GF Score
H. Lundbeck AS HLUBF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, H. Lundbeck AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.11/121.6800*121.6800
=1.110

Current CPI (Mar. 2026) = 121.6800.

H. Lundbeck AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2.870 100.600 3.471
201609 3.013 100.200 3.659
201612 3.037 100.300 3.684
201703 3.069 101.200 3.690
201706 3.271 101.200 3.933
201709 3.509 101.800 4.194
201712 3.561 101.300 4.277
201803 3.820 101.700 4.570
201806 3.711 102.300 4.414
201809 3.645 102.400 4.331
201812 3.032 102.100 3.613
201903 3.226 102.900 3.815
201906 3.232 102.900 3.822
201909 3.070 102.900 3.630
201912 3.550 102.900 4.198
202003 3.394 103.300 3.998
202006 3.320 103.200 3.915
202009 3.557 103.500 4.182
202012 3.516 103.400 4.138
202103 3.442 104.300 4.016
202106 0.646 105.000 0.749
202109 0.639 105.800 0.735
202112 0.620 106.600 0.708
202203 0.652 109.900 0.722
202206 0.642 113.600 0.688
202209 0.630 116.400 0.659
202212 0.671 115.900 0.704
202303 0.731 117.300 0.758
202306 0.719 116.400 0.752
202309 0.713 117.400 0.739
202312 0.734 116.700 0.765
202403 0.777 118.400 0.799
202406 0.797 118.500 0.818
202409 0.855 118.900 0.875
202412 0.785 118.900 0.803
202503 0.911 120.200 0.922
202506 0.935 120.700 0.943
202509 0.995 121.600 0.996
202512 0.963 121.200 0.967
202603 1.110 121.680 1.110

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $9.06 mean?
H. Lundbeck AS (HLUBF) has a Cyclically Adjusted Revenue per Share of $9.06 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on H. Lundbeck AS and its competitors.
Is H. Lundbeck AS's Cyclically Adjusted Revenue per Share too high?
H. Lundbeck AS's current Cyclically Adjusted Revenue per Share is $9.06. Overall, H. Lundbeck AS has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
H. Lundbeck AS's Cyclically Adjusted Revenue per Share of $9.06 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on H. Lundbeck AS and its competitors. H. Lundbeck AS's current Cyclically Adjusted Revenue per Share is $9.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (HLUBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.65, compared to a current price of $5.50 — trading 2.7% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $9.06. H. Lundbeck AS's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For H. Lundbeck AS (HLUBF), the current Cyclically Adjusted Revenue per Share is $9.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (HLUBF) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of $5.50 is trading 2.7% below its estimated GF Value™ of $5.65. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for HLUBF:

  • Cyclically Adjusted Revenue per Share: $9.06
  • GF Value™: $5.65 vs. price of $5.50 (2.7% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the HLUBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
78GF Score

Get the complete analysis for HLUBF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.50
Price
$5.65
GF Value